Strategic Partnerships

Depomed utilizes an aggressive partnering strategy to support its effort to build a portfolio of enhanced pharmaceutical products for large patient populations. The company’s partnering strategy is comprised of two key components – 

  • Out-license internally developed drugs to commercialization partners worldwide, while retaining rights to market products on its own to select market segments should it elect to do so;
  • Collaborate with companies looking to utilize Acuform™ delivery technology to enhance their own pharmaceutical products and possibly extend the product’s lifecycle.

Partnerships in Place

The following is a list of some of the commercialization and development partnerships Depomed currently has in place. To learn more about these partnerships, please visit the press release section of this website.

Commercialization Partnerships

Santarus, Inc.
Promotion agreement established in July 2008 for the U.S. commercialization of Glumetza (metformin hydrochloride extended release tablets) for type 2 diabetes mellitus.

Development and Commercialization Partnerships

Boehringer Ingelheim
License agreement established in March 2011 granting Boehringer Ingelheim worldwide rights to Acuform delivery technology for the development and commercialization of certain fixed dose combination product(s) which include extended release metformin and proprietary Boehringer Ingelheim compound(s) in development for type 2 diabetes.

Covidien
License and development agreement established in November 2008 granting Covidien an option to license Acuform delivery technology to develop and commercialize up to four pharmaceutical products.

Janssen Pharmaceutica
License agreement established in August 2010 granting Janssen Pharmaceutica worldwide rights to Acuform delivery technology for the development of a fixed dose combination formulation of canagliflozin, a Sodium Glucose Transport 2 (SGLT2) inhibitor, and extended-release metformin.

Patheon Inc.
Collaborative agreement established in August 2006 providing Patheon with access to Acuform technology for the purpose of formulating, developing or improving pharmaceutical products for the company’s clients and collaborative partners.

Partnership Opportunities

Depomed welcomes inquiries from companies interested in working together to develop enhanced pharmaceutical products, or to commercialize Depomed’s approved products.

The following is a list of partnering opportunities currently available with Depomed. To learn more, please contact the company’s business development department at busdev@depomedinc.com.

Development Opportunities

  • Serada™ (Menopausal Hot Flashes)
  • DM-1992 (Levodopa/Carbidopa)